2023年5月2日

吠檀多生物科學,臨床分期的公司正在開發一個潛在的新類別的口服療法基於定義的細菌財團——宣布它已經籌集了1.065億美元以支持臨床發展的領先候選人VE303預防複發的Clostridioides固執的感染(CDI)和一個第二階段的研究為潰瘍性結腸炎VE202,和其他開發活動。投資者財團是由新投資者共同安盛alt和AMR行動基金現有投資者比爾和梅林達•蓋茨基金會,Skyviews生命科學,重塑企業,Fiscus Ventures PEAK6這和大西洋海王星。新投資者K2 HealthVentures、韓國投資夥伴、韓國投資證券亞洲有限公司和韓國投資證券,和現有的投資者包括聯合創始人PureTech衛生,啟示夥伴,四投資管理,Seventure夥伴,漢布羅津貼,輝瑞也出席了會議。VE303研究:VE303研究將是第一個關鍵階段3的研究治療候選人基於定義細菌財團——吠檀多是開創性的新一代微生物組治療方法。並定義細菌細胞銀行財團是標準化的成分製造的產物,繞過需要依靠捐贈糞便的組成不一致。資金將用於:收益將推進的主要使用一個關鍵階段3 VE303研究複發性CDI和概念驗證階段2 VE202研究潰瘍性結腸炎。和吠檀多的積極VE303第二階段數據反複CDI最近發表在《美國醫學協會雜誌》(JAMA)。梭狀芽孢杆菌導致大約一百萬感染每年在美國,包括165000反複感染,和高達每年45000人的死亡有關。第二階段研究的積極成果,首次報道2021年10月,這引發了一個價值2380萬美元的合同選項從生物醫學高級研究和發展機構(BARDA)支持VE303的3期臨床研究。這個項目的部分資金就來自聯邦基金的健康和人類服務; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A5012C00177 for a contract value of up to $81.9 million. In conjunction with their investments, Curt LaBelle, M.D., Martin Heidecker, Ph.D., and Neil Tiwari will join Vedanta’s Board of Directors. Dr. And LaBelle has been investing in and working with healthcare companies for over 20 years and is the Managing Partner of Global Healthcare Strategies at AXA IM Alts. Dr. Heidecker brings over 20 years of extensive international experience in venture capital, drug development, and pharmaceutical marketing, and is the Chief Investment Officer of The AMR Action Fund. Tiwari brings over 15 years of healthcare experience in medical devices, pharmaceuticals, biotechnology, and health technology as an operator, investor, and board member, and is a healthcare, life sciences, and technology investor at Magnetar Capital. Plus 2 directors will conclude their tenure on Vedanta’s board, including Christopher Viehbacher, recently appointed Chief Executive Officer of Biogen, and Bharatt Chowrira, Ph.D., J.D., the President, Chief Business, Legal and Operating Officer of PureTech Health. And Charles Sherwood III, Associate General Counsel at PureTech, will replace Dr. Chowrira on the Vedanta Board of Directors. KEY QUOTES: “We are grateful to have the support of our new and existing investors, who share our vision of pioneering microbiome therapeutics based on defined bacterial consortia to transform the lives of patients with serious diseases. Our Phase 2 clinical data and this new funding enable us to continue advancing the microbiome field beyond products made from fecal donations, and towards pharmaceutical-grade, defined medicines.” — Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences “We extend our warm thanks to Chris and Bharatt for their several years of expert guidance and contributions to advancing our mission, and welcome our new Board members.” — Dr. Olle